The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
The management of HR-positive, HER2-negative metastatic breast cancer includes endocrine
monotherapy or combination regimens, both with benefit diminishing as resistance develops.
Nowadays, various studies have demonstrated that estrogen interacts with many angiogenic
pathways and is an important mechanism for resistance leading to the question of whether
combination with antiangiogenesis and antiestrogen therapies could be an appropriate
therapeutic modality. Anlotinib is a novel multi-target tyrosine kinase inhibitor that
effectively inhibit VEGFR, FGFR, PDGFR, c-KIT, c-MET and RET. Previous studies have proven
the efficacy of both anlotinib monotherapy and combination regimens in advanced breast
cancer. This phase II study aims to preliminarily evaluate the efficacy and safety of
anlotinib combined with endocrine therapy.